Trends, Charts and Exclusive Opinion
Theres Never Been a Better Time
HALO: Signs Research Collaboration with BioAtla
INSP: Revenues Increase 92% from Q4 2008
BIOD: FDA Accepts Marketing Application
Gaining 13% this morning is Halozyme Therapeutics Inc., (HALO) http://www.halozyme.com/ currently trading in the $6.20 range on a 3-Month average daily trading volume of 375,540 shares. HALO is widely held by insiders and institutions. One year ago in March of 09, HALO was trading in the $4 range. HALO doubled its value trading up to $8 in June. With a slight dip or two, HALO held a $7.50 floor for the next 5-Months before winding down prior to the 09 holidays to find the $5.50. HALO is now moving back up... HALO has a 52-Week high of $8.09 set on 06-08-09. There are a few more short-sellers in this stock than I’d like, but not enough to put any downward pressure on the value. HALO is a short-term (6 Mo) ‘Buy’ consideration for me.
In Jan, HALO signed a research collaboration with BioAtla aimed at discovering potential treatments for cancer and other conditions. HALO Halozyme will receive exclusive worldwide commercial rights for treatments discovered during the initial three-year term of the collaboration, during the initial three-year term. HALO and BioAtla will focus on developing treatments for cancer and inflammatory conditions, a well as for aesthetic skin uses.
Sign-Up for Free to Receive Future Commentary and
Trading Alerts on HALO, INSP, and BIOD.
Next up today is S&P SmallCap 600 company InfoSpace Inc., (INSP) http://www.infospaceinc.com/ currently trading in the $10.97 range on a 3-Month average daily trading volume of 335,755 shares. Between April and Aug of 09 INSP set a 5-Month trading floor of $7. For the next 5-Months, INSP set a floor of $8. INSP apparently sets a floor and sticks to it for months. The stock shot up to $12 in Jan 2010 and has leveled off in the $10 range (setting a new floor). INSP has a 52-Week high of $12.16 set on 01-07-10. INSP has trailing twelve month revenues of $207+ million with a positive, corresponding diluted EPS of +$0.28. INSP is also a short-term ‘Buy’ consideration for me.
INSP provides search services through its Web sites, such as Dogpile.com, WebCrawler.com, MetaCrawler.com, and WebFetch.com, as well as through the Web properties of distribution partners. Its customers are primarily search content providers.
INSP had Q4 09 revenues of $70.5 million, reflecting a $33.7 million, or 92%, increase from Q4 08. Revenues for the year were $207.6 million in 09, reflecting a $50.9 million, or 32%, increase over 08. Net income for Q4 09 was $10.1 million, or $0.28 per diluted share, compared to net loss of $7.9 million, or $0.23 per share, for Q4 08. Nice turnaround.
Guidance given at the time of its Q4 for Q1 2010 was: revenue to be between $60 million and $65 million. INSP expects Adjusted EBITDA to be between $6 million and $7 million and net income to be between $0.5 million and $1.5 million, or $0.01 and $0.04 per diluted share.
Finally, Bio-Pharma Biodel Inc., (BIOD) http://www.biodel.com/ currently trading in the $4.32 on a 3-Month average daily trading volume of 246,071 shares has something to cheer about: Approval. Since April of 09, BIOD has essentially been trading in the $5 range, but took a dip in late Oct 09 to $3.50. BIOD staged an inverted ‘V’ back above $5 and dipped (while waiting on a drug application approval) back to $3.50. Its Feb 2010 ascent began from the $3.50 and it is now headed back to $5 and beyond... BIOD has a 52-Week high of $6.02 set on 06-12-09. BIOD is also a short-term ‘Buy’ consideration for me.
BIOD has a niche in and focuses on the development and commercialization of treatments for diabetes; a huge problem in the U.S. and frankly; everywhere. Today, the FDA accepted the BIOD marketing application for its experimental diabetes drug VIAject. BIOD expects the regulatory action date for the VIAject application to be Oct. 30. VIAject is a formulation of regular human insulin that is designed to be absorbed into the blood faster than currently marketed rapid-acting insulin products. When the drug is out of trials and approved. BIOD will soar.
If you'd like to receive further updates and any changes in our opinions of HALO, INSP, and BIOD, be sure to Sign-Up for the SCN Newsletter today! It's FREE.